Genome-Wide Analyses of Aggressiveness in Attention-Deficit Hyperactivity Disorder

Erlend J. Brevik,1,2,3* Marjolein M.J. van Donkelaar,4 Heike Weber,5 Cristina Sánchez-Mora,6,7,8 Christian Jacob,9 Olga Rivero,10 Sarah Kittel-Schneider,10 Iris García-Martínez,6,7 Marcel Aebi,11,12 Kimm van Hulzen,4 Bru Cormand,13,14,15 Josep A. Ramos-Quiroga,6,7,8,16 IMAGE Consortium, Klaus-Peter Lesch,9,17 Andreas Reif,5 Marta Ribasés,6,7,8 Barbara Franke,4,18 Maj-Britt Posserud,1,2 Stefan Johansson,19,20 Astri J. Lundervold,2,3 Jan Haavik,1,2 and Tetyana Zayats2*

1Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
2K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway
3Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway
4Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
5Department of Psychiatry, Psychosomatics and Psychotherapy, University of Frankfurt, Frankfurt, Germany
6Psychiatric Genetics Unit, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
7Department of Psychiatry, Hospital Vall d’Hebron, Barcelona, Spain
8Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain
9Department of Psychiatry and Psychotherapy, Klinik Nürtingen, Nürtingen, Germany
10Department of Molecular Psychiatry, Center of Mental Health, University of Würzburg, Würzburg, Germany
11Department of Forensic Psychiatry, Child and Youth Forensic Service, University Hospital of Psychiatry, Zurich, Switzerland
12Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland
13Facultat de Biologia, Departament de Genètica, Universitat de Barcelona, Catalonia, Spain
14Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain
15Institut de Biomedicina de la Universitat de Barcelona (IBUB), Catalonia, Spain
16Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
17Department of Translational Neuroscience, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands
18Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
19Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
20Department of Clinical Science, University of Bergen, Bergen, Norway

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Grant sponsor: K.G. Jebsen Foundation for Medical Research; Grant sponsor: University of Bergen; Grant sponsor: Western Norwegian Health Authorities (Helse Vest); Grant sponsor: European Community’s Seventh Framework Programme; Grant number: FP7/2007–2013; Grant sponsor: Research and Innovation Program; Grant numbers: 602805, H2020; Grant sponsor: Marie Sklodowska-Curie; Grant number: 643051 (MIND); Grant sponsor: Deutsche Forschungsgemeinschaft; Grant numbers: DFG: KFO 125, TMR 58/AS, DFG RE1632/5–1; Grant sponsor: Fritz Thyssen Foundation; Grant number: Az.10.13.1185; Grant sponsor: Jacobs Foundation; Grant sponsor: Spanish Ministerio de Economía y Competitividad; Grant number: SAF2012-33484; Grant sponsor: AGAUR; Grant number: 2014SGR932; Grant sponsor: Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Spain; Grant sponsor: Instituto de Salud Carlos III-FIS, Spain; Grant numbers: PI11/00571, PI11/01629, PI12/01139, PI14/01700; Grant sponsor: Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR Generalitat de Catalunya; Grant number: 2014SGR1357; Grant sponsor: Departament de Salut, Government of Catalonia, Spain; Grant sponsor: NIH; Grant numbers: R01MH62873, R01MH081803; Grant sponsor: European College of Neuropsychopharmacology.

Correspondence to:
Erlend J. Brevik, PsyD, and Tetyana Zayats, M.D., Ph.D., K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway.
E-mail: erlend.brevik@psybp.uib.no (EJB); tetyana.zayats@uib.no (TZ)

Manuscript Received: 23 June 2015; Manuscript Accepted: 9 February 2016

© 2016 The Authors. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics Published by Wiley Periodicals, Inc.
Aggressiveness is a behavioral trait that has the potential to be harmful to individuals and society. With an estimated heritability of about 40%, genetics is important in its development. We performed an exploratory genome-wide association (GWA) analysis of childhood aggressiveness in attention deficit hyperactivity disorder (ADHD) to gain insight into the underlying biological processes associated with this trait. Our primary sample consisted of 1,060 adult ADHD patients (aADHD). To further explore the genetic architecture of childhood aggressiveness, we performed enrichment analyses of suggestive genome-wide associations observed in aADHD among GWA signals of dimensions of oppositionality (defiant/vindictive and irritable dimensions) in childhood ADHD (cADHD). No single polymorphism reached genome-wide significance ($P < 5.00E-08$). The strongest signal in aADHD was observed at rs10826548, within a long noncoding RNA gene (beta = $-1.66$, standard error (SE) = 0.34, $P = 1.07E-06$), closely followed by rs35974940 in the neurotrimin gene (beta = 3.23, SE = 0.67, $P = 1.26E-06$). The top GWA SNPs observed in aADHD showed significant enrichment of signals from both the defiant/vindictive dimension (Fisher’s $P$-value = 2.28E-06) and the irritable dimension in cADHD (Fisher’s $P$-value = 0.0061). In sum, our results identify a number of biologically interesting markers possibly underlying childhood aggressiveness and provide targets for further genetic exploration of aggressiveness across psychiatric disorders. © 2016 The Authors. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics Published by Wiley Periodicals, Inc.

Key words: ADHD; aggression; GWAS

INTRODUCTION

Aggressiveness can be defined as any behavior directed toward an individual with the immediate intent to cause harm [Anderson and Bushman, 2002]. Violence, which is strongly related to aggressiveness, is the sixth leading cause of burden of disease for people aged 15–44 years worldwide [WHO, 2008]. To date, most interventions designed to reduce violence risk typically have small effects, reflecting our limited understanding of its causes and stressing the need for further studies [Moffitt, 2005; McGuire, 2008].

As a complex phenomenon, aggressiveness spans across numerous facets of human behavior, ranging from emotional lability and temperamental traits (e.g., hot-tempered, short fuse, irritable) to physical violence [Lesch et al., 2012]. These traits are frequently found among youth with attention deficit hyperactivity disorder (ADHD), a common child and adolescent psychiatric disorder with a prevalence of about 5% and a rate of persistence into adulthood of about 50% [Faraone et al., 2015]. ADHD is defined by symptoms of inattention and hyperactivity/impulsivity, and youth with ADHD often have co-existing disorders, some of which are closely related to aggressiveness and violence, such as conduct disorder (CD) and/or oppositional defiant disorder (ODD) and disorders characterized by symptoms defined within the broader term of antisocial behavior [Dalsgaard et al., 2002]. These disorders put youth with ADHD at high risk of problems associated with aggressiveness in adulthood [Klassen et al., 2010], especially when the aggressive behavior has an early onset [Hofvander et al., 2009].

This can be illustrated by the fact that around 30% of youth and 25% of adult prison inmates are found to qualify for an ADHD diagnosis [Young et al., 2014]. Studies of childhood aggressiveness in adults can, therefore, be of great importance to improve our understanding of adult ADHD.

The etiology of ADHD as well as traits of aggressiveness is complex, with genetics playing an important role. The heritability of ADHD has been estimated to be up to 88% across the lifespan [Larsson et al., 2013], whereas the estimates of genetic influence on aggression vary across studies, collectively reaching about 40–50% [Brendgen et al., 2006; Tuvblad and Baker, 2011]. Such diversity in the estimation of aggression heritability may result from inconsistency in measures across studies. Several different aggression measures have been utilized to assess the genetic and environmental influences on its development [Veroude et al., 2015], reflecting that there is no consensus regarding its definition [Ramirez and Andreu, 2006]. Furthermore, the estimates of aggressiveness are influenced by the age of the study participants. The literature reports stability of aggressiveness between childhood and adulthood, with adolescence as a transient period with little stability in this trait [Moffitt, 2005]. Genes seem to explain little variation in adolescent aggression, but are likely to account for individual differences in childhood and adult aggression [Lyons et al., 1995]. Also, given higher levels of aggression in males and higher genetic load in males with antisocial behavior compared to females, it is an open question whether genetic propensity is of greater importance in one sex over the other [Miles and Carey, 1997; Tuvblad and Baker, 2011]. Interestingly, similar considerations of age and sex effects are also present in studies of ADHD as well as when ADHD is co-morbid with aggressive behavior [Faraone et al., 1991, 2015].

Given that ADHD and aggression often co-occur and that both traits are heritable, twin studies have noted the possibility of shared genetic etiology between ADHD and aggression. A common genetic factor has been reported among ADHD and symptoms of aggression in 9–10-year-old children [Tuvblad et al., 2009]. Likewise, it has been suggested that impulsivity and aggression are genetically mediated to a similar extent [Serczynski et al., 1999].

Influenced by major theories on neuronal circuits, genetic association studies of ADHD and/or aggression have been dominated by candidate gene studies, focusing on the regulation of
... monoaminergic transmission [Faraone et al., 2015; Veroude et al., 2015]. In line with twin studies, these candidate gene analyses have provided further support toward a shared genetic component between ADHD and aggression. Many genes associated with ADHD point toward the same biological mechanisms as those associated with aggressive behavior, including genes that are involved in the synthesis, binding, transport and degradation of neurotransmitters, especially dopamine and serotonin [Faraone et al., 2015; Veroude et al., 2015]. It has been reported, for example, that the genes MAOA, DRD2, DRD4, COMT, SLC6A4, TPH1, and TPH2 may contribute to the development of ADHD as well as aggressive behaviors [Gizer et al., 2009; Vassos et al., 2014]. However, these candidate gene studies suffer from the lack of replication in independent samples (where available) and small effect sizes suggest that some of these genes play a more limited role in the susceptibility to ADHD and/or aggressive behavior, or that their involvement may be limited to rare familial cases [McKinney et al., 2008; Halmoy et al., 2010; Tiilhonen et al., 2014]. Thus, the overall genetic architecture of ADHD and/or aggression remains largely unknown and warrants studies using a hypothesis-free approach [Vassos et al., 2014].

Genome-wide association (GWA) studies allow interrogation of the entire genome to generate new hypotheses. To date, few GWA studies have been performed for ADHD and/or aggressiveness, with no finding passing the stringent Bonferroni-corrected genome-wide significance level ($P < 5.00E-08$) for either phenotype [Dick et al., 2011; Tiellbeek et al., 2012; Mick et al., 2014; Salvatore et al., 2015]. Nonetheless, as these studies were generally underpowered, some understanding of biological processes behind ADHD and/or aggressiveness may emerge from the convergence of identified nominally significant loci. Previous GWA studies on aggressive behaviors in ADHD have noted a number of suggestive association signals, generating biological hypotheses regarding the etiology of ADHD and/or aggression [Anney et al., 2008; Aebi et al., 2015]. In addition, a recent GWA study revealed a positive linear correlation between ADHD polygenic scores and comorbid aggression scores, indicating that the presence of aggressive symptoms in ADHD is likely to index a greater genetic load [Harmshere et al., 2013]. Similarly hypothesis-free, genome-wide linkage analyses have also reported evidence of significant co-segregation between ADHD and disruptive behavior [Jain et al., 2007].

The lack of robust genetic association signals may be explained by the modest sample sizes and the complex nature of both ADHD and aggressiveness, where genetic factors are intertwined with environmental influences [Breindgen et al., 2006]. In addition, heterogeneity in genetic susceptibility, phenotypic manifestation, and operationalization of aggressiveness may depress association signals [Cross-Disorder Group of the Psychiatric Genomics et al., 2013]. The phenotypic heterogeneity in ADHD may potentially be exacerbated by its high rates of comorbidity with not only aggressive behaviors, but also mood and anxiety disorders [Biederman et al., 1992]. Another possible reason behind the lack of replicable genetic findings is the limited annotation of the human genome. The annotation has mostly been focused on protein-coding genes that represent only $\sim 1\%$ of our genome, making it difficult to evaluate possible biological pathways involved in ADHD and/or aggressiveness, as the majority of GWA findings tend to reside outside the traditional protein-coding regions [Dick et al., 2011; Schizophrenia Working Group of the Psychiatric Genomics, 2014].

In the present study, we aimed to perform exploratory genome-wide association tests to shed light on the genetic susceptibility loci and biological processes possibly involved in the etiology of childhood aggressiveness in ADHD. We utilized the GWA method to analyze childhood aggressiveness in adults with ADHD gathered in studies across Europe. To minimize phenotypic heterogeneity between samples, we derived our measure of childhood aggressiveness in adult ADHD (aADHD) from the Wender Utah Rating Scale (WURS). This questionnaire was used as part of the assessment procedure at all sites. As the WURS reflects childhood recollections, we also explored a possible genetic overlap of association signals observed in aADHD with those of irritable and defiant/vindictive dimensions of ODD in youth with ADHD (cADHD) [Aebi et al., 2015]. Finally, we performed an examination of non-protein coding genes in order to obtain a better understanding of the biological processes underlying childhood aggressiveness in aADHD.

**MATERIALS AND METHODS**

**Subjects**

**aADHD samples.** Recruitment of adult ADHD patients was conducted at three sites within an international multicenter persistent ADHD collaboration (IMPACT, http://www.impactadhdgenomics.com): Germany, Norway, and Spain. All individuals were of Caucasian ancestry. Only participants who gave written informed consent were enrolled in the studies, which complied with the Declaration of Helsinki.

**German sample.** Patients with a diagnosis of aADHD were recruited by experienced psychiatrists at the University of Würzburg (Würzburg, Germany). Unrelated in- and outpatients of self-reported central-European descent completed a semi-structured clinical interview according to DSM-IV. Inclusion criteria were onset before the age of 7 years, lifelong persistence, current diagnosis and age of recruitment between 18 and 65 years. Exclusion criteria were the appearance of symptoms restricted to the duration of any other Axis I disorder; current diagnosis of active alcohol or other drug abuse or dependence; lifetime diagnosis of bipolar I disorder, schizophrenia, or any other psychotic disorder; and an IQ score below 80. For a more detailed sample description, please confer previous publications [Reif et al., 2009; Franke et al., 2010]. The study was approved by the Ethic Committee of the University of Würzburg (Würzburg, Germany).

**Norwegian sample.** Participants were recruited at the University of Bergen (UiB, Bergen, Norway) as described elsewhere [Halmoy et al., 2009]. In short, adult patients with ADHD were recruited through a Norwegian national medical registry as well as by psychologists and psychiatrists working at outpatient clinics. All patients had been previously diagnosed with ADHD using either DSM-IV or ICD-10. The ICD-10 criteria were adapted to the DSM-IV criteria by allowing the inattentive subtype as sufficient for the ADHD diagnosis. Individuals with other neuropsychiatric disorders were not excluded as long as the ADHD criteria were fulfilled.

**Scale (WURS).** This questionnaire was used as part of the assessment procedure at all sites. As the WURS reflects childhood recollections, we also explored a possible genetic overlap of association signals observed in aADHD with those of irritable and defiant/vindictive dimensions of ODD in youth with ADHD (cADHD) [Aebi et al., 2015]. Finally, we performed an examination of non-protein coding genes in order to obtain a better understanding of the biological processes underlying childhood aggressiveness in aADHD.
Individuals with IQ below 70 were excluded from the study. All participants provided either blood or saliva samples for DNA extraction. The study was approved by the regional committee for medical and health research ethics, western Norway.

**Spanish sample.** Participants were recruited at the Department of Psychiatry from the Hospital Universitari Vall d’Hebron (HUHV, Barcelona, Spain) as described elsewhere [Sanchez-Mora et al., 2015]. Patients were adults of Caucasian origin and met Diagnostic and Statistical Manual for Mental Disorders-IV (DSM-IV) criteria for ADHD. The diagnosis of ADHD was evaluated with the Structured Clinical Interview for DSM-IV Axis I and II Disorders (SCID-I and SCID-II) and the Conner’s Adult ADHD Diagnostic Interview for DSM-IV (CAADDI Parts I and II). Consensus eligibility criteria for the current study were a diagnosis of ADHD according to the diagnostic criteria of DSM-IV, onset before the age of 7 years via retrospective diagnosis (which was confirmed by a family member, wherever possible), lifelong persistence and current diagnosis. DNA was extracted from either peripheral blood or saliva samples. The study was approved by the ethics committee of the institution.

**cADHD sample.** Youth with ADHD were participants in the International Multicentre ADHD Genetics (IMAGE) study, recruited in 12 children and adolescent psychiatry clinics representing eight countries across Europe. Approval was obtained by the Institutional Review Board of SUNY Upstate Medical University and from ethical review boards within each country. A detailed description of the study design and assessment procedures has been provided in previous publications [Muller et al., 2011a,b]. In short, entry criteria for probands were a clinical diagnosis of ADHD according to DSM-IV-based structured interviews and access to one or both biological parents and one or more full siblings for DNA collection and clinical assessment. Exclusion criteria included autism, epilepsy, IQ < 70, brain disorders, and any genetic or medical disorder associated with externalizing behaviors that might mimic ADHD.

**Measures of Aggressiveness**

**aADHD samples.** The adult measure of childhood aggressiveness in the aADHD samples was derived from the Wender Utah Rating Scale (WURS) [Ward et al., 1993]. The WURS is a questionnaire used for retrospective assessment of childhood symptoms of ADHD in adults. An exploratory factor analysis (EFA) was run to determine the latent structure of the WURS. The EFA consisted of a principal component analysis with Varimax rotation and yielded three factors with Eigen values above one. The dimensions of oppositionality were assessed using the long form of the revised Conners Parent Rating Scale (CPRS-R:L) [Conners et al., 1998]. The defiant/vindictive and irritable dimensions of ODD were defined on theoretical grounds as described elsewhere [Aebi et al., 2015], and reflect two previously described dimensions of ODD [Stringaris et al., 2012; Aebi et al., 2013].

**Genotype Data**

Genotyping of each sample was performed by each of the four participating groups, individually. To maximize available genetic information among examined datasets, genetic imputation was carried out independently at each site.

**aADHD Samples**

**German sample.** Genotyping of participants was performed on Illumina’s PsychChip array (Illumina, San Diego, CA) at the Broad Institute (Cambridge, MA) using the PsychChip 15048346 B manifest. Genotypes were assigned in Illumina’s GenomeStudio v2010.3, using the calling algorithm/genotyping module version 1.8.4. Quality control procedures were performed as described previously, with lightly modified exclusion criteria (SNPs exhibiting missingness above 98%; minor allele frequency below 5%; failing Hardy–Weinberg equilibrium test \( P < 10^{-4} \)) [Zayats et al., 2015]. Genotype imputation was performed with SHAPEIT/IMPUTE2 pipeline as described elsewhere, using 1000 Genomes Phase 3 data as a reference [Marchini et al., 2007; Howie et al., 2009; Cross-Disorder Group of the Psychiatric Genomics, 2013].

**Norwegian sample.** Participants were genotyped on Human OmniExpress-12v1-1_B (Illumina, San Diego, CA) platform at the deCODE Genetics facility (Reykjavik, Iceland). Genotyping and quality control procedures are described elsewhere [Zayats et al., 2015]. Imputation was performed utilizing IMPUTE software as previously detailed [Marchini et al., 2007; Howie et al., 2009; Cross-Disorder Group of the Psychiatric Genomics, 2013].

**Spanish sample.** Genome-wide genotyping was performed with the Illumina HumanOmni1-Quad BeadChip platform. Quality control was implemented at the individual and SNP level using PLINK and included filtering subjects with low call rate (<98%) or gender discrepancy followed by filtering SNPs with minor allele frequency (MAF) < 0.01, Hardy–Weinberg equilibrium test \( P \)-values < 1e-06 or call rate < 0.99 in either cases or controls. Imputation was performed using BEAGLE software [Browning and Browning, 2007].

**cADHD sample.** Sample collection and DNA isolation has been described previously [Brookes et al., 2006]. Genome-wide genotyping and quality control was performed as part of the GAIN study using the Perlegen 600 K genotyping platform, as previously described [Neale et al., 2008]. The imputation was performed using MACH and the Hapmap 2 (Release 22 Build 36) reference data set [Li et al., 2010]. Quality control was performed on the imputed data, and SNPs with imputation quality scores lower than 0.30, a

...
minor allele frequency lower than 0.01, and those failing the Hardy–Weinberg equilibrium test at a threshold of $P \leq 10^{-5}$ were excluded. SNPs and subjects with missingness rates higher than 0.05 were removed from the data.

Statistical Analyses

The age and gender distributions between the aADHD and cADHD samples were assessed using $\chi^2$ for gender and ANOVA for age.

**Gene-wide association (GWA) of aggressiveness.** In the aADHD sample, single nucleotide polymorphisms (SNPs) were tested for association with the WURS-derived measure of aggressiveness in the form of linear regression carried out in PLINK using post-imputation dosage data [Purcell et al., 2007]. Regression models were adjusted for age and sex. Genotype data of each site were first processed individually. The results were then combined with the use of fixed-effects inverse variance meta-analysis in METAL [Willer et al., 2010]. Only SNPs with minor allele frequency (MAF) equal to or above 1% and imputation INFO measure equal to or above 0.6 were included in the analyses. Genomic control, QQ plotting, and regional plotting of top loci were applied to check the integrity of test statistics [Devlin and Roeder, 1999; Cuellar-Partida et al., 2015]. The genomic inflation factor was calculated using METAL [Willer et al., 2010]. A genome-wide significance threshold of 5.00E-08 was adopted to correct for multiple testing.

GWA analyses of irritable and defiant/vindictive dimensions of ODD in cADHD sample was performed in PLINK software in the form of linear regression adjusted for sex and age [Purcell et al., 2007]. Details of the analyses are described elsewhere [Aebi et al., 2015].

**Gene-based and Gene-set association of aggressiveness in the aADHD meta-analyzed sample.** Gene-based and gene-set pathway analysis were performed in the aADHD sample carried out in MAGMA software [de Leeuw et al., 2015]. First, a degree of gene-based tests was calculated for each gene based on METAL-derived individual SNPs’ $P$-values, using 1000 Genomes CEU dataset as a reference panel to correct for linkage disequilibrium (LD) [Genomes Project et al., 2012]. To evaluate each gene’s contribution to examined gene-sets (gene-set pathway analysis), the $P$-value of each gene was converted to a $Z$-value and used as an outcome variable in a regression model with gene-set membership as a predictor. Gene size and gene-sets’ gene density were added as covariates to adjust for possible confounding effects and prevent spurious association.

For gene-based tests, we assessed the association with both protein and non-protein-coding genes. The protein-coding gene list was curated from the catalog of known genes downloaded from the Genome Browser of the University of California Santa Cruz (UCSC, CA). The non-protein-coding genes were examined in the form of long non-coding RNA (lncRNA) genes detailed in the aforementioned catalog. For gene-set pathway analysis, we examined structural categories of gene ontology (GO, http://geneontology.org), with respect to cellular function, biological process and cellular compartments. To achieve meaningful statistics and interpretation of the results, we restricted our pathway analysis to those GO terms that contained SNPs in at least 10 genes per term in our aADHD data.

**Genome-wide enrichment analyses between GWA results in aADHD and cADHD samples.** Prior to performing enrichment analyses, the genetic data in both aADHD and cADHD samples were pruned to remove correlated loci in linkage disequilibrium (LD) with each other. A pairwise correlation coefficient ($r^2$) threshold of 0.2 and the 1000 Genomes CEU reference dataset were used to identify independent SNPs, as previously described [Lindgren et al., 2009; Genomes Project et al., 2012].

Enrichment was examined by means of Fisher’s test performed in the R software, assessing the difference in proportion of SNPs revealing association $P$-values below 0.05 in the cADHD sample according to suggestive association in the aADHD sample (P-value below or equal to 1.00E-03 versus P-value above 1.00E-03) [Rahmioglu et al., 2015]. Consistency in directionality of SNP effects with indication of enrichment between aADHD and cADHD samples was tested as linear regression on the effect (beta) of each SNP for aADHD as an outcome and for cADHD (either irritable or defiant/vindictive dimensions of ODD, respectively) as predictor variables [Do et al., 2013].

**Examination of previously reported aggressiveness-related candidate GWA loci.** We assembled a list of previously reported candidate GWA loci associated with aggressive behavior by systematic literature search the catalog of published genome-wide association studies provided by National Human Genome Research Institute (NHGRI) ([https://www.genome.gov/26525384](https://www.genome.gov/26525384)), using key words of “aggression,” “anger,” “violence,” as well as “conduct disorder” and “antisocial personality disorder.” Each identified candidate GWA locus was then looked up in meta-analyzed aADHD sample.

RESULTS

**Subjects, Measure of Aggressiveness, and GWA Analyses**

In total, 1,060 adult patients as well as 750 children and adolescents with ADHD were available for the analyses. The age ranges in the aADHD samples were 17–75 in the German sample, 18–57 in the Norwegian sample, and 17–60 in the Spanish sample. In the cADHD sample, the age range was 5–17. Details of the final samples are summarized in Table I. Supplementary Figure S1 presents the distribution of the selected measure of aggressiveness in each aADHD dataset. After quality control of imputed SNPs in the adult samples, 9,301,568 SNPs were available for the analyses in the German sample, 8,910,491 SNPs in the Norwegian sample, and 6,683,176 SNPs in the Spanish sample. Among these three datasets, 7,576,458 autosomal SNPs were present in at least two and, thus, were meta-analyzed to assess genetic architecture of childhood aggressiveness in aADHD. In cADHD sample, 1,871,025 autosomal SNPs were available for the analyses.

Individual GWA analyses revealed no genome-wide significant hits ($P \leq 5.00E-08$) in either aADHD sample (not shown) nor in the cADHD sample (Supplementary Table S1 and Fig. S2). None of the variants in the meta-analysis reached the Bonferroni-corrected genome-wide significance level ($P \leq 5.00E-08$) either. The strongest signal was observed at rs10826548 on chromosome 10 located within the transcript of a long noncoding RNA (lncRNA) (beta $= -1.66$, $P$-value $= 2.06E-10$).
standard error (SE) = 0.34, P-value = 1.07E-06 (Fig. 1), closely followed by rs35974940 in the neurotrimin (NTM) gene (beta = 3.23, SE = 0.67, P-value = 1.26E-06) (Fig. 2). Top associated markers (P ≤ 1.0E-05) are summarized in Supplementary Table SII. The genomic inflation factor was close to one for all individual and meta-GWA analyses in aADHD. QQ plots of GWA analyses in aADHD are presented in Supplementary Figure S3.

Gene-Based and Gene-Set Association of Aggressiveness in the aADHD Meta-Analyzed Sample

Among annotated protein-coding genes, 17,595 had more than one SNP present in the aADHD data. The strongest signal was noted for the WD repeat domain 62 (WDR62) gene (P-value = 4.84E-05). Supplementary Table SIII summarizes the top protein-coding genes (P ≤ 1.0E-03) observed in aADHD sample. None of the protein-coding gene-based tests survived the correction for multiple testing.

Among lncRNA genes, 22,696 had more than one SNP present in our aADHD data. The strongest association was observed for ENST00000427806 (P-value = 3.04E-05). The top lncRNA genes (P ≤ 1.0E-03) detected in this study are reported in Supplementary Table SIV. None of the non-protein-coding gene-based tests survived the correction for multiple testing.

Among GO pathways, 1,945 terms contained SNPs in at least 10 genes per term in the aADHD data. The most prominent association was observed for negative regulation of I-kappaB kinase/NF-kappaB signaling pathway (GO:0043124 term, P-value = 7.26E-04). Supplementary Table SV reports top GO terms (P ≤ 0.01) recognized in this study. None of the GO pathways survived the correction for multiple testing.

Genome-Wide Enrichment Analyses Between GWA Results in aADHD and cADHD Samples

To assess potential genome-wide overlap of association signals between measures of childhood aggressiveness in aADHD and cADHD, we investigated the independent (r² < 0.2) GWA signals of suggestive significance (P ≤ 1.0E-03) in aADHD for enrichment in GWA signals of either defiant/vindictive or irritable dimensions in cADHD. Given our modest sample size, only those SNPs were considered in cADHD results that revealed a P-value below or equal to 0.05 to avoid the examination of effects with a wide confidence interval. The top GWA SNPs of WURS-derived childhood aggressiveness in aADHD showed significant enrichment of signals from both the defiant/vindictive dimension (Fisher’s P-value = 2.28E-06) and the irritable dimension in cADHD GWA analysis (Fisher’s P-value = 0.0061; Fig. 3A).

Next, we examined the directionality of effects of variants with association signals in both aADHD and cADHD samples (P ≤ 1.0E-03 in aADHD and P < 0.05 in cADHD). Significant correlation between betas was observed in assessment of both oppositional dimensions in cADHD and childhood aggressiveness in aADHD (P = 0.0053 and 0.0045 for defiant/vindictive and irritable dimensions respectively), but the direction of the relationship was negative (Figs. 3B and C). Supplementary Table SVII summarizes the top hits (P ≤ 1E-00E-05) observed in GWA meta-analysis of childhood aggressiveness in aADHD and their corresponding statistics observed in cADHD.
reported to be associated with CD symptom count in ADHD patients. The same SNP also revealed nominally significant association in the same direction with the defiant/vindictive dimension (beta = −0.54, SE = 0.21, P-value = 0.0094), but not with the irritable dimension in cADHD. In this result, one should keep in mind that the cADHD described here is a subsample of the sample in which the original finding for rs4889240 was described [Aebi et al., 2015]. Full results of our literature search are presented in Supplementary Table SVIII.

**DISCUSSION**

In this study, we performed a genome-wide exploration of childhood aggressiveness as reported retrospectively by adult patients with ADHD (aADHD), examining both conventional protein-coding and lncRNA genes. We also explored the overlap with parent-reported oppositional behavior in youth with ADHD (cADHD) and evaluated previously reported aggression-related GWA loci. Given our modest sample size (1060 aADHD patients)
and the anticipated small effect of common polymorphisms in complex traits, it is not surprising that we did not observe any genome-wide significant SNPs ($P < 5.00E-08$). Nonetheless, we were able to identify several nominally significant variants ($P < 1.00E-05$) in biologically interesting genes for follow-up studies of aggressiveness in ADHD, a feature of the disorder that has received little attention so far.

The strongest signal in the performed single-point GWA tests of childhood aggressiveness in aADHD was noted for rs10826548 (beta = -1.16, SE = 0.34, $P = 1.07E-06$, Supplementary Table SI). This variant resides in the transcript of a lncRNA with uncertain coding potential (TCONS_00018147) (Fig. 1). Non-protein coding RNAs play a critical role in the regulation of gene expression and have been previously associated with neuropsychiatric disorders, including ADHD [Perkins et al., 2005; Gonzalez-Giraldo et al., 2015; Zayats et al., 2015]. In addition, it has recently been observed that SNPs previously associated with neurological and psychiatric conditions may be highly...
concentrated in the regions of long non-protein coding RNA genes [Ning et al., 2014].

The second most significant locus identified in this study is located within the neurotrimin (NTM) gene (intronic rs35974940, \( P = 1.26E-06 \), Supplementary Table SI and Fig. S2). NTM is a protein-coding gene, encoding a member of glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules, containing immunoglobulin (Ig) domain. These proteins are predominantly expressed in the central nervous system (CNS) [Struyk et al., 1995].

Among the association signals observed in NTM gene, several have the potential to alter its expression. As determined in the TRANSFAC database implemented in the SNPinfo server of the National Institute of Environmental Health Sciences (http://snpinfo.niehs.nih.gov), rs34588147 and rs35665773 (GWA \( P \)-values of 3.59E-06 and 3.25E-06, respectively, Supplementary Table SI) are transcription factor binding sites (TFBS) (Fig. 2). Moreover, two other SNPs in high linkage disequilibrium with the aforementioned ones (rs12804059 and rs7119590, \( r^2 = 1 \) in CEU population) also represent TFBS. Notably, differential expression of NTM between two major brain regions linked to aggression subtypes—prefrontal cortex and amygdala—was observed in early prenatal stage of human brain development (\( P = 0.015 \), http://www.brainspan.org).

Gene expression regulation during neuronal development as one of the possible mechanisms behind aggressiveness in aADHD was further affirmed by our top associated lncRNA gene—ENST00000427806 (\( P = 3.04E-05 \), Supplementary Table SIV). The target gene of this lncRNA has been predicted to be the protein-coding ST6

FIG. 3. Enrichment and direction of effect among GWA signals of oppositional dimensions in cADHD and WURS-derived childhood aggressiveness in aADHD. Part A reflects the proportion of SNPs nominally associated (\( P < 0.05 \)) with each examined oppositional dimension in cADHD (defiant/vindicitive and irritable) among suggestive signals (\( P < 1.00E-03 \)) of association with childhood aggressiveness in aADHD. Reported \( P \)-values are those of Fisher’s exact test. Parts B and C reflect directions of effect of 24 independent nominally significant loci in GWA analyses of defiant/vindicitive dimension in cADHD and childhood aggressiveness in aADHD (part B) as well as 17 independent nominally significant loci in GWA analyses of irritable dimension in cADHD and childhood aggressiveness in aADHD (part C). Linear regression \( r^2 \) measures and \( P \)-values are shown.
As the adult measure of aggressiveness was derived from self-reported experiences in childhood, we examined the possibility of overlap of its GWA signals with those from GWA analyses of two oppositional dimensions in a cADHD sample. We observed a slight enrichment of association signals between the nominally associated loci in aADHD and those observed in the GWA of both the defiant/vindictive and the irritable ODD dimensions examined in cADHD (Fig. 3). However, it is noteworthy that the aADHD and cADHD samples were imputed using different reference panels with disparate genomic coverage.

Surprisingly, the correlation between the direction of effects of the aforementioned SNPs was negative (Fig. 3B and C). Such an inverse relationship in effect directionality between parent-reported ODD dimensions and adult retrospective report of childhood aggressiveness is most likely a chance finding due to our small sample size. It might also be related to phenotypic and genetic heterogeneity of the examined samples. There were considerable differences in the percentage of females between the aADHD and the cADHD samples (Table I), which could indicate such mechanisms. It has been shown that both age and sex are important factors in genetic influences in ADHD and aggression [Lyons et al., 1995; Miles and Carey, 1997; Tuvblad and Baker, 2011; Faraone et al., 2015]. In addition, the aggressiveness in the cADHD sample was determined by parent-report, whereas in the aADHD sample, it was based on retrospective self-report. The correlation between parent-report and self-report has been shown to be generally poor [Achenbach et al., 1987], as also discussed in a recent study that found little overlap between samples of cADHD and aADHD [Moffitt et al., 2015]. Hence, the measures of aggressiveness in the cADHD and the aADHD samples are different. Furthermore, the youth and adult ADHD samples may also be heterogeneous because childhood ADHD does not always persist into adulthood [Faraone et al., 2006; Moffitt et al., 2015]. Thus, to gain better understanding of the genetic overlap between childhood aggression in aADHD and oppositional dimensions in cADHD, this relationship should be examined in larger sample using more rigorous statistical methods, such as those developed to test specifically for genetic correlation among various traits [Yang et al., 2011; Bulik-Sullivan et al., 2015a,b]. This was not possible to implement in the current study due to our modest sample size.

Examination of previously reported aggressiveness-related GWA loci revealed modest commonality in genetic architecture between the childhood measures of aggressiveness in both cADHD and aADHD, as well as in CD and anti-social personality disorder (Supplementary Table SVIII). This observation may be in line with formerly reported phenotypic overlap between these conditions, although to which extent this overlap can be transmitted to various subtypes of aggressiveness remains to be determined [Storebo and Simonsen, 2013].

This study should be viewed in light of its limitations. One explanation for not observing any genome-wide significant loci (P < 5.00E-08) could be our relatively modest sample size and examination of common variants only (MAF > 1%). This study had 63% power to detect common variants with small effect size of explaining 0.5% of variability under an additive model and an alpha level of 0.05 (http://genome.sph.umich.edu/wiki/Power_Calculations:Quantitative_Traits). This may also be observed in the distribution of the QQ plots (Supplementary Fig. S3).

Another explanation for the lack of significant findings may lay in phenotypic variability. Clinical heterogeneity may weaken true association signals due to the use of different assessment protocols or real genetic heterogeneity among subtypes of ADHD [McClellan and King, 2010]. There are several methodological caveats to assessing aggressiveness [Moffitt et al., 2015]. As our samples consist of outpatients, we investigate a broader and perhaps ‘softer’ aspect of aggressiveness than say, for example, if we were to study prison inmates and/or juvenile offenders. However, this approach provides us with access to the vast majority of aggressive behaviors, which may not come to be written in official records [Moffitt, 2005]. Furthermore, we lack assessment of different subtypes of aggressive behavior that may be related to different genotypes.

Considering the different direction of effects and different measures of aggression in the cADHD and the aADHD samples, analyzing the adult samples and the youth sample together could potentially have obscured the genetic association signal. This is why we refrained from performing meta-analysis across all samples. Nonetheless, the WURS includes a host of symptoms related to various elements of aggressiveness, which, based on our factor analysis as well as previous research [Ward et al., 1993] seem to be of key importance to the phenotype of aADHD, and the ODD measures have also been validated in previous studies of cADHD [Stringaris et al., 2012; Aebi et al., 2013]. Our approach may add to the discussion of the Negative Valence System in the Research Domain Criteria (RDoC) of the National Institute of Mental Health (NIMH) of how to conceptualize and operationalize aggressiveness as a dimension across different samples and disorders [Verona and Bresin, 2015; Veroude et al., 2015].

We lacked information on current substance abuse in our aADHD sample. Substance abuse is known to be frequently comorbid with ADHD and may confound the relationship between ADHD and current aggressiveness. However, we utilized a retrospective measure of childhood aggressiveness that is likely to reflect behavior over a longer period of time and should, thus, be less affected by volatile environmental influences [Gulberg-Kjær and Johansson, 2009].

Finally, since the genome-wide genotyping arrays consist of SNPs only, we were not able to assess the contribution of previously reported variable tandem repeats (e.g., those in MAOA) that were noted to be associated with aggressive behaviors and/or ADHD. Taken together with evidence from previous studies, our results implicate mechanisms of cell adhesion as well as regulation of gene expression in the etiology of childhood aggressiveness in ADHD. As there is a substantial degree of overlap in aggressiveness among neuropsychiatric disorders, it could be beneficial to analyze
conditions where aggression is present together in order to pinpoint biological processes in dysfunctional forms of aggressiveness. Further studies including samples of both children, adolescents and adults, adopting multimodal measures and longitudinal designs are warranted. Such studies may help our understanding as to which extent various subtypes of aggression are mediated by different mechanisms.

ACKNOWLEDGMENTS

This work was supported by the KG Jebsen Foundation for Medical Research, University of Bergen, the Western Norwegian Health Authorities (Helse Vest), European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement no 602805 and H2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement number 643051 (MiND).

The sample used in this part is of the international multicentre persistent ADHD collaboration (ImpACT). ImpACT unites major research centres working on the genetics of ADHD persistence across the lifespan and has participants in the Netherlands, Germany, Spain, Norway, the United Kingdom, the United States of America, Brazil, and Sweden. Principal investigators of ImpACT are Barbara Franke (chair), Andreas Reif, Stephen V. Faraone, Jan Haavik, Bru Cormand, Antoni Ramos Quiroga, Philip Asherson, Klaus-Peter Lesch, Jonna Kuntsi, Claiton Bau, Jan Buitelaar, Stefan Johansson, Henrik Larsson, Alysa Doyle, and Eugenio Greve.

This study was also funded by Deutsche Forschungsgemeinschaft (DFG: KFO 125 and TRR 58/A5 to KPL; DFG RE1632/5-1 to AR), Fritz Thyssen Foundation (Az.10.13.1185 to KPL and OR), and Jacobs Foundation (to OR).

Dr. Cormand received financial support from the Spanish “Ministerio de Economía y Competitividad” (SAF2012-33484) and AGAUR (2014SGR932).

Marta Ribasés is a recipient of a Miguel de Servet contract from the “Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación,” Spain. Financial support was received from “Instituto de Salud Carlos III-FIS,” Spain (PI11/00571, PI11/01629, PI12/01139, PI14/01700), “Agència de Gestió d’Ajuts Universitari i de Recerca-AGAUR Generalitat de Catalunya” (2014SGR1357), and “Departament de Salut,” Government of Catalonia, Spain.

The International Multisite ADHD Genetics (IMAGE) project is a multi-site, international effort. Funding support for the IMAGE project was provided by NIH grants R01MH62873 and R01MH081803 to SV. Faraone and the genotyping of samples was provided through the Genetic Association Information Network (GAIN). The dataset used for the analyses described in this manuscript were obtained from the database of Genotypes and Phenotypes (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number #20726-2. Samples and associated phenotype data for the IMAGE Project were provided by the principal investigators Stephen V. Faraone, Philip Asherson, Tobias Banaschewski, Jan Buitelaar, Richard P. Ebstein, Michael Gill, Ana Miranda, Fernando Mulas, Robert D. Oades, Herbert Roeyers, Aribert Rothenberger, Joseph Sergeant, EDMUND Sonuga-Barke, and Hans-Christoph Steinhausen, the chief investigators at each site, Rafaela Marco, Nanda Rommelse, Wai Chen, Henrik Uebel, Hanna Christiansen, Ueli C. Mueller, Catheljne Bushgens, Barbara Franke, and Margaret Thompson, as well as the statistical analysis team, M. Daly, C. Lange, N. Laird, J. Su, and B. Neale.

We wish to thank the support received from the European College of Neuropsychopharmacology (ECNP network: “ADHD across the lifespan”).

REFERENCES


Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, ReproGen C, C Psychiatric Genomics, C Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control, Duncan L.


SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher’s web-site.